Cargando…
Orally Administered Natural Lipid Nanoparticle-Loaded 6-Shogaol Shapes the Anti-Inflammatory Microbiota and Metabolome
The past decade has seen increasing interest in microbiota-targeting therapeutic strategies that aim to modulate the gut microbiota’s composition and/or function to treat chronic diseases, such as inflammatory bowel disease (IBD), metabolic symptoms, and obesity. While targeting the gut microbiota i...
Autores principales: | Yang, Chunhua, Long, Dingpei, Sung, Junsik, Alghoul, Zahra, Merlin, Didier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472296/ https://www.ncbi.nlm.nih.gov/pubmed/34575431 http://dx.doi.org/10.3390/pharmaceutics13091355 |
Ejemplares similares
-
Prevention of Colitis-Associated Cancer via Oral Administration of M13-Loaded Lipid Nanoparticles
por: Long, Dingpei, et al.
Publicado: (2023) -
Prevention of Ulcerative Colitis by Autologous Metabolite Transfer from Colitogenic Microbiota Treated with Lipid Nanoparticles Encapsulating an Anti-Inflammatory Drug Candidate
por: Yang, Chunhua, et al.
Publicado: (2022) -
Preparation and Characterization of IL-22 mRNA-loaded Lipid Nanoparticles
por: Alghoul, Zahra, et al.
Publicado: (2023) -
The Current Status of Molecular Biomarkers for Inflammatory Bowel Disease
por: Alghoul, Zahra, et al.
Publicado: (2022) -
Impact of PepT1 deletion on microbiota composition and colitis requires multiple generations
por: Viennois, Emilie, et al.
Publicado: (2020)